Download in electronic PDF format for $25



Search the Complete Journal Archives

Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time

Author(s):  Sanchez-Rubio Ferrandez J, Lozano M C, Iglesias I, Sanchez-Rubio Ferrandez L, Rodriguez Vargas B, Moreno Diaz R

Issue:  Sep/Oct 2012 - Volume 16, Number 5
View All Articles in Issue

Abstract:  PhaSeal is a closed-system drug transfer device which has demonstrated to protect against occupational exposure to antineoplastic agents. Our aim was to assess the impact of the incorporation of PhaSeal on the processing time of chemotherapy. The study was a prospective simulation study which compared the processing times with the traditional open-system technique and using the closed-transfer system. Four experienced pharmacy technicians prepared six batches with each method simulating simple chemotherapy admixture operations. We compared the mean times obtained by student's t test and evaluated the “learning effect” between days by ANOVA. The average percentage of time saving with PhaSeal was 31.7% (time per batch [mean±SD] 6.44+0.73 vs. 9.44+0.98 minutes). Mean difference was statistically significant (3.0 min IC95% 2.50-3.50; p>0.0001). No significant learning curve effect was detected. The BD Medical/Carmel Pharma PhaSeal system, in addition to its protective properties, is able to save time in the elaboration process which leads to organization advantages for hospital pharmacy services.

Related Keywords: J. Sanchez-Rubio Ferrandez, PhD Pharmacy, M. C. Lozano, PhD Pharmacy, I. Iglesias, PhD Pharmacy, L. Sanchez-Rubio Ferrandez, PhD Pharmacy, B. Rodriguez Vargas, PhD Pharmacy, R. Moreno Diaz, PhD Pharmacy, closed-system drug transfer, chemotherapy agents, occupational exposure, preparation time

Related Categories: CANCER AND AIDS, PEER-REVIEWED, TECHNOLOGY, PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time Sanchez-Rubio Ferrandez J, Lozano M C, Iglesias I, Sanchez-Rubio Ferrandez L, Rodriguez Vargas B, Moreno Diaz R Sep/Oct 2012 431-433 Buy
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr Jan/Feb 2018 7-16 Buy
PreScription: Compounding Pharmacy Issues for 2017 Allen Loyd V Jr Jan/Feb 2017 4 Buy
The BPS Pharmacy Specialty Certification Program Bertin Richard J May/Jun 1999 200 Buy
Regulatory and Operational Issues of Founding a Compounding Pharmacy Smith Lisa K Nov/Dec 2002 434-437 Buy
Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh Allen Loyd V Jr Nov/Dec 2003 449-450 Buy
PostScription: Guidance to Achieve Accreditation from the Pharmacy Compounding Accreditation Board Pharmacy Compounding Accreditation Board Sep/Oct 2010 440-441 Buy
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug Mar/Apr 2017 95-102 Buy
PostScription: Innovative Community Pharmacy Practice: Past, Present, and Future Huffman D C Jul/Aug 2010 350-351 Buy
PostScription: Profile of a Pharmacy Compounding Accreditation Board Accredited Pharmacy: Avera Doctors Plaza 2 Pharmacy Hoffman Karen Nov/Dec 2010 531 Buy